Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis
Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 11, 2026, 07:30 ET Multi-target therapeutic aims to treat all key and interconnected problems of atopic dermatitis ANNAPOLIS, Md., March 11, 2026 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing the first Multi-Target…